NBIX News and Press, Neurocrine Biosciences Inc. From 09/14/23

2023-09-14 08:54:47 ET More on Neurocrine Seeking Alpha’s Quant Rating on Neurocrine Biosciences Neurocrine Needs A Meaningful Clinical Win To Break Out, And Crinecerfont Could Do It Neurocrine Biosciences: Ingrezza Impresses Amid Costly Pipeline Expansion Eff...

Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA® (valbenazine) Oral Granules Sprinkle Formulation PR Newswire Prescription Drug User Fee Act (PDUFA) Target Action Date Set for April 30, 2024 SAN DIEGO , Sept. 14, 2...

2023-09-12 14:05:37 ET More on Spruce Seeking Alpha’s Quant Rating on Spruce Biosciences Historical earnings data for Spruce Biosciences Financial information for Spruce Biosciences Spruce Biosciences: H2 2023 Data Could Be A Game Changer For CAH Treat...

2023-09-12 11:57:12 ET More on Neurocrine Seeking Alpha’s Quant Rating on Neurocrine Biosciences Historical earnings data for Neurocrine Biosciences Financial information for Neurocrine Biosciences Neurocrine Needs A Meaningful Clinical Win To Break Ou...

Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH) PR Newswire CAHtalyst ™ Met Primary Endpoint Demonstrating a Statistically Significant Decrease from ...

NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditions NBI-1117570 is the second compound to advance into clinical development from a portfolio of selec...

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults PR Newswire SAN DIEGO , Sept. 11, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Pha...

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September PR Newswire 2023 Wells Fargo Healthcare Conference on September 7 in Boston Morgan Stanley 21 st Annual Global Healthcare Conference on September 12 in New York ...

Neurocrine Biosciences Presents Data at MDS International Congress of Parkinson's Disease and Movement Disorders® Demonstrating Comparable Improvement Over Time in Tardive Dyskinesia Severity and Impact Following Treatment With INGREZZA® (valbenazine) Capsules PR Newswire ...

2023-08-28 10:50:19 ET More on Neurocrine Biosciences Neurocrine Needs A Meaningful Clinical Win To Break Out, And Crinecerfont Could Do It Neurocrine Biosciences: Ingrezza Impresses Amid Costly Pipeline Expansion Efforts BMO upgrades Neurocrine to market perform on ...